NCT07022977CompletedPhase 1
A Study of MET233 in Individuals With Obesity or Overweight
A Randomized, Double-blind, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MET233 in Otherwise Healthy Adult Participants With Obesity or Overweight
Source: ClinicalTrials.gov · Last updated 26 May 2026
Brief summary (registry, in English)
The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity. This study will be conducted in four parts: * Part A will evaluate single ascending doses of MET233 or placebo. * Part B will evaluate multiple ascending doses, with participants receiving five once-weekly doses of MET233 or placebo. * Part C will evaluate once-weekly dosing of MET233 or placebo for 12 weeks, followed by a single higher, potential monthly dose. * Part D will evaluate a longer dosing schedule, in which participants will receive twelve once-weekly doses, followed by three monthly doses of MET233 or placebo. Participants in this part will be followed for 14 weeks after the final dose.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 144 (actual)
- First submitted
- 6 Jun 2025
- Start date
- 6 Nov 2024
- Primary completion date
- 21 Apr 2026
- Lead sponsor
- Pfizer
- Diseases
- Obesity
- NCT number
- NCT07022977
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 144
- From 6 Nov 2024 to the primary completion date, 21 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Female who is lactating or who is pregnant according to the pregnancy test at the Screening visit or prior to the first study drug administration
- Participation in a weight loss program with or without pharmacotherapy during the 3 months prior to study administration
Other illness
- Diagnosis of diabetes (type 1 or type 2)
- Obesity induced by endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., Melanocortin 4 Receptor deficiency or Prader-Willi Syndrome).
Other
- Seated blood pressure higher than 160/95 mmHg at the Screening visit
- Elevated resting pulse greater than 100 beats per minute at Screening visit
- Presence of clinically significant ECG abnormalities
Who the study is looking for
- Adult (≥18 to ≤70 years) male and female participants with obesity or overweight (BMI 27.0 kg/m2 to 38.0 kg/m2, inclusive) but otherwise healthy.
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Altasciences Clinical Los Angeles, Inc Coordinator of this site? Confirm its status | Cypress | United States | Unknown status |
Related publications
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.Peptides · 2026 · PMID 41747885
This page is information, not medical advice. Discuss any trial with your doctor.